Gazyva
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10132 NW 7th St Unit 203, Miami, Florida...Website
www.gazyva.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Gazyva
GAZYVA (obinutuzumab) is a prescription medication used for the treatment of adult patients with previously untreated or relapsed follicular lymphoma and chronic lymphocytic leukemia. It is administered in conjunction with chemotherapy drugs, followed by GAZYVA alone for those who respond positively to the initial treatment. The product is intended for adult patients and healthcare professionals in the United States. Important safety information and potential side effects, including serious reactions, are provided for patient awareness.Explore more
Popular SearchesGazyvaGaziva LLCGenentech IncSIC Code 28,283NAICS Code 32,325Show moreGazyva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gazyva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Gazyva had a recent Job posting/layoffs
Check out if Gazyva is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Gazyva
Earning: See what the market has to say on Gazyva recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Gazyva launches new products
Funding: Get notified immidiatlly once Gazyva has new funding data
Gazyva, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Gazyva has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Gazyva
Compare insights from companies similar to Gazyva, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Gazyva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gazyva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gazyva.
Gazyva Tech Stack
A closer look at the technologies used by Gazyva
See more technologies
Gazyva News & Media
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points. One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points.As Roche/Genentech’s Obinutuzumab (Gazyva) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
The white paper illustrates how recent lupus launches, including Lupkynis (Aurinia), Benlysta (GSK), and Saphnelo (AstraZeneca), showcase the critical role of strategic differentiation and targeted education in driving future uptake. The white paper illustrates how recent lupus launches, including Lupkynis (Aurinia), Benlysta (GSK), and Saphnelo (AstraZeneca), showcase the critical role of strategic differentiation and targeted education in driving future uptake.FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva® (obinutuzumab) for the treatment of lupus nephritis. The filing acceptance is based on positive results from the Phase III REGENCY study, which showed improved complete renal response (CRR) with Gazyva plus standard therapy compareNew England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in people with active lupus nephritis (LN) was published in the New England Journal of Medicine. The trial demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of complete renal response (CRR), showing that 46.4% of people treated with
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gazyva
Sign Up For FreeTo access detailed company insights
GAZYVA (obinutuzumab) is a prescription medication used for the treatment of adult patients with previously untreated or relapsed follicular lymphoma and chronic lymphocytic leukemia. It is administered in conjunction with chemotherapy drugs, followed by GAZYVA alone for those who respond positively to the initial treatment. The product is intended... Read More
